Total Payments
$1.6M
2024 Payments
$91,773
Companies
34
Transactions
1,371
Payment Breakdown by Category
Consulting$876,629 (56.4%)
Other$393,593 (25.3%)
Research$148,667 (9.6%)
Travel$120,126 (7.7%)
Food & Beverage$15,631 (1.0%)
Education$57.29 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $876,629 | 253 | 56.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $324,336 | 121 | 20.9% |
| Unspecified | $148,667 | 121 | 9.6% |
| Travel and Lodging | $120,126 | 488 | 7.7% |
| Honoraria | $69,257 | 33 | 4.5% |
| Food and Beverage | $15,631 | 353 | 1.0% |
| Education | $57.29 | 2 | 0.0% |
Payments by Type
General
$1.4M
1,250 transactions
Research
$148,667
121 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $565,367 | 411 | $0 (2024) |
| PFIZER INC. | $451,680 | 355 | $0 (2024) |
| Eli Lilly and Company | $119,107 | 108 | $0 (2024) |
| GlaxoSmithKline, LLC. | $81,079 | 56 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $76,410 | 90 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $43,067 | 58 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $29,066 | 52 | $0 (2020) |
| Lilly USA, LLC | $28,732 | 25 | $0 (2019) |
| EMD Serono, Inc. | $28,500 | 5 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $18,266 | 85 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $91,773 | 108 | PFIZER INC. ($32,606) |
| 2023 | $121,832 | 147 | ABBVIE INC. ($31,672) |
| 2022 | $168,100 | 164 | ABBVIE INC. ($69,978) |
| 2021 | $197,171 | 65 | PFIZER INC. ($89,536) |
| 2020 | $162,519 | 79 | AbbVie Inc. ($114,020) |
| 2019 | $310,024 | 337 | AbbVie, Inc. ($144,884) |
| 2018 | $229,292 | 275 | PFIZER INTERNATIONAL LLC ($99,359) |
| 2017 | $273,991 | 196 | PFIZER INC. ($84,143) |
All Payment Transactions
1,371 individual payment records from CMS Open Payments — Page 1 of 55
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| 11/19/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $81.48 | General |
| 11/19/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $56.42 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $47.30 | General |
| 11/19/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.62 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $9.44 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $154.76 | General |
| 11/18/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $81.48 | General |
| 11/18/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $56.42 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: Immunology | ||||||
| 11/17/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $81.48 | General |
| 11/17/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $56.42 | General |
| Category: Immunology | ||||||
| 11/17/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.29 | General |
| 11/17/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $81.48 | General |
| 11/16/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $56.42 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.94 | General |
| 11/16/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,006.40 | General |
| 11/15/2024 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $2,960.00 | General |
| 11/15/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,081.60 | General |
| Category: Immunology | ||||||
| 11/15/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $127.42 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $96.39 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $93.95 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $24,050 | 14 |
| BIOSIMILARS I I CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $16,290 | 10 |
| A PHASE 3 MULTICENTER STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $11,432 | 4 |
| M13-741 | AbbVie, Inc. | $9,000 | 2 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | ABBVIE INC. | $9,000 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,186 | 1 |
| A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate Inadequate Responders with Rheumatoid Arthritis | Amgen Inc. | $5,319 | 1 |
| A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequa | SANOFI-AVENTIS U.S. LLC | $5,146 | 11 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | AbbVie Inc. | $5,112 | 8 |
| TOFACITINIB RA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,530 | 2 |
| EPOETIN ZETA MULTI PRODUCT PRINABEREL INFLIXIMAB HOSPIRA ADALIMUMAB PFIZER INFLIXIMAB PFIZER CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA) | GENZYME CORPORATION | $2,680 | 2 |
| TARGET | SANOFI-AVENTIS U.S. LLC | $2,567 | 7 |
| 4-Year Results from the RAPID-PsA Phase 3 Randomized Placebo-Controlled Trial of Certolizumab Pegol in Psoriatic Arthritis | UCB, Inc. | $2,300 | 1 |
| Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients | UCB, Inc. | $2,300 | 1 |
| Similar efficacy and safety of sarilumab 150 mg or 200 mg q2w regardless of primary or secondary failure with TNF inhibitors | SANOFI-AVENTIS U.S. LLC | $1,827 | 2 |
| XELJANZ CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,820 | 1 |
| Efficacy of Sarilumab in Combination With csDMARDs in Patients With Rheumatoid Arthritis and Inadequate Response to TNF Inhibitors by Baseline Levels of Disease Activity - 2470 | SANOFI-AVENTIS U.S. LLC | $1,716 | 1 |
| Improvements in Remission and Low Disease Activity Are Achieved With Ongoing Sarilumab Treatment, in Patients With Rheumatoid Arthritis in 2 Phase 3 Studies - 2480 | SANOFI-AVENTIS U.S. LLC | $1,716 | 1 |
| Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active, Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or In | SANOFI-AVENTIS U.S. LLC | $1,716 | 1 |
| EPOETIN ZETA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
| Long-Term Safety of Sarilumab in Rheumatoid Arthritis: An Integrated Analysis with up to 7 Years? Follow-Up | SANOFI-AVENTIS U.S. LLC | $1,162 | 2 |
| Efficacy and Safety of Sarilumab in Combination with csDMARDs or as Monotherapy in Subpopulations of Patients with Moderately to Severely Active Rheumatoid Arthritis in Three Phase III Randomized, Con | SANOFI-AVENTIS U.S. LLC | $1,147 | 2 |
| Interleukin-6 receptor blockade or TNF inhibition for reducing glycemia in patients with RA and diabetes: Post Hoc Analyses of Three Randomized, Controlled Trials | SANOFI-AVENTIS U.S. LLC | $1,147 | 2 |
| Effect of Sarilumab on Glycosylated Hemoglobin in Patients with Rheumatoid Arthritis and Diabetes | SANOFI-AVENTIS U.S. LLC | $1,136 | 3 |
| A multi-center, uncontrolled extension study evaluating the efficacy and safety of sarilumab in patients with active Rheumatoid Arthritis (SARIL-RA-EXTEND) | SANOFI-AVENTIS U.S. LLC | $1,117 | 2 |
| Long-Term Safety with Sarilumab Monotherapy or with csDMARDs in Rheumatoid Arthritis: An Integrated Analysis of over 8,000 Patient-Years Follow-Up | SANOFI-AVENTIS U.S. LLC | $1,061 | 1 |
| A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF- antagonists | GENZYME CORPORATION | $1,020 | 2 |
| MOBILITY-TARGET MONARCH Pooled Subpopulations | SANOFI-AVENTIS U.S. LLC | $922.53 | 1 |
| Safety, efficacy and glycemic control of sarilumab among patients with rheumatoid arthritis and diabetes | SANOFI-AVENTIS U.S. LLC | $922.53 | 1 |
| The Effect of Sarilumab in Combination With DMARDs on Fasting Glucose and Glycosylated Hemoglobin in Patients With Rheumatoid Arthritis With and Without Diabetes - 1822 | SANOFI-AVENTIS U.S. LLC | $900.78 | 1 |
| A randomized, double-blind, parallel-group study assessing the efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis | GENZYME CORPORATION | $893.33 | 1 |
| Certolizumab Pegol Provides Sustained Remission and Minimal Disease Activity in Patients with Psoriatic Arthritis Over 4 Years Treatment | UCB, Inc. | $820.00 | 1 |
| TOFACITINIB SPA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $780.00 | 1 |
| A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) | ABBVIE INC. | $750.00 | 1 |
| PRINABEREL CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $620.00 | 1 |
| Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to tumor necrosis factor inhibitors | SANOFI-AVENTIS U.S. LLC | $530.00 | 1 |
| Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis with 1 or >1 prior tumor necrosis factor inhibitor failures | SANOFI-AVENTIS U.S. LLC | $530.00 | 1 |
| Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of The BRASS Registry | SANOFI-AVENTIS U.S. LLC | $491.33 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of | SANOFI-AVENTIS U.S. LLC | $483.24 | 1 |
| Long-Term Safety with Sarilumab+csDMARD and Sarilumab Monotherapy: An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) Follow-Up | SANOFI-AVENTIS U.S. LLC | $442.20 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy | SANOFI-AVENTIS U.S. LLC | $423.87 | 1 |
| Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients (RA-MOBILITY) | SANOFI-AVENTIS U.S. LLC | $423.87 | 1 |
| The Effect of Certolizumab Pegol on Radiographic Progression Over 4 Years of Treatment in Patients with Psoriatic Arthritis | UCB, Inc. | $420.00 | 1 |
| Glucocorticoid Dose is Progressively Reduced in Patients with Rheumatoid Arthritis Receiving Sarilumab: Results from the Open-Label EXTEND Study | SANOFI-AVENTIS U.S. LLC | $402.00 | 1 |
| The Effect of Certolizumab Pegol on Extra-Articular Manifestations of Psoriatic Arthritis Over 4 Years of Treatment in Patients With and Without Prior Anti-TNF Exposure | UCB, Inc. | $400.00 | 1 |
| Associations between rheumatoid arthritis disease activity and patient-reported outcomes in sarilumab clinical trials | SANOFI-AVENTIS U.S. LLC | $353.33 | 1 |
| A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA_MONARCH) | SANOFI-AVENTIS U.S. LLC | $266.33 | 1 |
| A PHASE I/II, OPEN-LABEL, PARALLEL-GROUP, DOSE ESCALATION AND EXPANSIO | GlaxoSmithKline, LLC. | $254.48 | 5 |
| Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND) | SANOFI-AVENTIS U.S. LLC | $225.12 | 1 |
| MOBILITY | SANOFI-AVENTIS U.S. LLC | $198.42 | 2 |
About Dr. Roy Fleischmann, M.D
Dr. Roy Fleischmann, M.D is a Specialist healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1467451146.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roy Fleischmann, M.D has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $91,773 received in 2024. These payments were reported across 1,371 transactions from 34 companies. The most common payment nature is "Consulting Fee" ($876,629).
Ad
Practice Information
- Specialty Specialist
- Location Dallas, TX
- Active Since 07/15/2005
- Last Updated 09/09/2009
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1467451146
Products in Payments
- XELJANZ (Drug) $343,273
- RINVOQ (Biological) $141,531
- Humira (Biological) $133,951
- RINVOQ (Drug) $95,319
- KEVZARA (Drug) $31,264
- ORENCIA (Biological) $30,330
- COSENTYX (Biological) $19,687
- TREMFYA (Drug) $18,266
- RETACRIT (Biological) $14,160
- Rinvoq (Biological) $12,761
- HUMIRA (Biological) $12,649
- Enbrel (Biological) $12,020
- SKYRIZI (Biological) $11,743
- Rituxan (Biological) $7,758
- KEVZARA (Biological) $6,555
- Cimzia (Drug) $6,240
- ABRILADA (Biological) $5,425
- ACTHAR (Biological) $4,375
- Otezla (Drug) $3,965
- KRYSTEXXA (Drug) $1,408
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Dallas
Dr. William Lumry, M.d, M.D
Specialist — Payments: $2.4M
Specialist $2.4M
Dr. Marc Tribble, M.d, M.D
Specialist — Payments: $763,573
Specialist $763,573
Stephen Hohmann, Md, MD
Specialist — Payments: $551,635
Specialist $551,635
Dr. William Adams, M.d, M.D
Specialist — Payments: $350,194
Specialist $350,194
Clinton Bell, M.d, M.D
Specialist — Payments: $273,947
Specialist $273,947
Dennis Gable, Md, MD
Specialist — Payments: $243,097
Specialist $243,097